Tumor-targeted multifunctional extracellular vesicles as drug carriers for lung cancer therapy

Chemotherapy remains a cornerstone of lung cancer treatment, but its benefits are often limited by serious side effects. Drugs like cisplatin can damage healthy tissues as they circulate through the body, leading to toxicity that restricts dosing and impacts quality of life. Finding better ways to deliver these drugs directly to cancer cells while sparing normal cells is a major goal in cancer therapy.

Researchers at the University of Oklahoma Health Sciences Center explored a promising solution using extracellular vesicles, which are small, naturally produced particles that cells use to transport molecules. Because extracellular vesicles can be taken up efficiently by cells and modified for targeting, they are attractive candidates for drug delivery.

In their work, the team engineered tumor-targeted multifunctional extracellular vesicles, designed specifically for lung cancer therapy. These vesicles were loaded with gold nanoparticles carrying the chemotherapy drug cisplatin. The drug was attached using a pH-sensitive linkage, allowing it to be released more efficiently in acidic environments like those found inside tumors. To further improve targeting, the researchers decorated the surface of the vesicles with transferrin, a molecule that binds the transferrin receptor, which is highly expressed on many lung cancer cells.

Laboratory experiments showed that these engineered vesicles were about 138 nanometers in size and released more drug under acidic conditions than at normal physiological pH. When tested on lung cancer cell lines, the vesicles were especially effective against cells with high transferrin receptor levels. They caused greater cancer cell death, increased DNA damage, and higher levels of apoptosis compared to non-targeted vesicles or free cisplatin.

Importantly, the same vesicles caused much less toxicity in normal lung fibroblasts and kidney cells. This suggests that packaging chemotherapy drugs inside targeted extracellular vesicles can improve their cancer-killing ability while reducing harmful effects on healthy tissues.

Overall, this research highlights how combining nanotechnology with extracellular vesicle engineering may lead to safer and more precise chemotherapy strategies for lung cancer and potentially other cancers.